Creyon Bio

Creyon Bio is a private, pre-clinical biotech company pioneering a novel approach to RNA drug delivery using aptamers and artificial intelligence. Its core technology platform aims to overcome key limitations of traditional antibody-based delivery and lipid nanoparticles by enabling precise, cell-specific targeting of therapeutic payloads like siRNA and ASOs. The company has established preclinical proof-of-concept in three therapeutic areas—immunology, CNS, and neuromuscular diseases—and is advancing a wholly-owned pipeline. Creyon represents a convergence of next-generation delivery science and computational drug design, positioning it to develop potentially safer and more effective RNA therapies.

Proprietary aptamer delivery technology for cell-specific targeting of oligonucleotide payloads (siRNA, ASO) and LNPs, coupled with an AI-powered nucleic acid engineering platform (NuclelQ™) for de-risked drug design.

Creyon competes in the crowded and rapidly evolving field of targeted RNA delivery. Competitors include companies using antibody-oligonucleotide conjugates (e.g., Avidity Biosciences), advanced LNP technologies, and other peptide or small molecule targeting approaches. Its differentiation lies in the combination of aptamer delivery and an integrated AI design platform.